1122 search results for:

Avacta Group, a clinical stage oncology drug company and developer of diagnostics based on its innovative Affimer and pre|CISION platforms, has been granted Orphan Drug Designation (ODD) by the US FDA of the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.

Swedish medtech start-up Capitainer says its qDBS card has scored highly in a major new study published in Clinica Chimica Acta on the advantages of volumetric microsampling DBS devices in monitoring of patients with phenylketonuria (PKU). The study was necessary according to the authors, because although measurement of dried blood spot phenylalanine (Phe) is central […]

Lifespin, based in Regensburg, Germany, with offices in Boston, Massachusetts, has launched a new commercial service that, for the first time, will provide the pharma­ceutical and biobanking industry with access to its proprietary metabolic database, as well as its advanced interpretive software to assist in various phases of drug research, development, and manufacturing.

BD (Becton, Dickinson and Company) and Accelerate Diagnostics, an innovator of rapid in-vitro diagnostics in microbiology, announced a worldwide commercial collaboration agreement where BD will offer Accelerate’s rapid testing solution for antibiotic resistance and susceptibility. The test offers results in hours, versus one to two days with some traditional laboratory methods.